Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8598241 | 0.88 | HDAC1 (0.66) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 | |
| SCHEMBL444059 | 0.85 | PTPN1 (0.67) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 | |
| SCHEMBL3527398 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 | |
| SCHEMBL29435967 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 | |
| SCHEMBL27529851 | 0.81 | PTPN1 (0.73) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 | |
| SCHEMBL29435966 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 | |
| SCHEMBL4108418 | 0.81 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 | |
| SCHEMBL11253655 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 | |
| SCHEMBL30848559 | 0.81 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 | |
| SCHEMBL6008184 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EHPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103619892-B | Phenolic resin and underlayer film forming material for lithography | 三菱瓦斯化学株式会社 | 2016-08-24 | — | — | CN | disclosed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| EP-1727526-A2 | PIPERAZINE UREA DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | Schering Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| EP-1713483-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | Schering Aktiengesellschaft (DE) | 2006-10-25 | — | — | EP | disclosed |
| CN-1279026-C | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LAB (US) | 2006-10-11 | — | — | CN | disclosed |
| US-7115591-B2 | Pyridazinone compounds as cyclooxygenase [COX] 2 inhibitorsfor gastrointestinal disorders | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | BAUMAN JOHN G | 2006-06-22 | — | — | US | disclosed |
| EP-1660089-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MYOCARDITIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| CN-1342149-A | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LAB (US) | 2002-03-27 | — | — | CN | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | SMN1; SMN2 4516/4885KDM4E 2385/4885HPGD 13/4885 |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | SMN1; SMN2 4729/4885KDM4E 1780/4885HPGD 198/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | SMN1; SMN2 4250/4885KDM4E 2161/4885HPGD 1458/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | SMN1; SMN2 4648/4885KDM4E 1071/4885HPGD 48/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | SMN1; SMN2 4516/4885KDM4E 2385/4885HPGD 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.